COVID19 - Medical Countermeasures

Coronavirus Protein Structure

The need to rapidly develop new medical countermeasures is critical for enabling a timely response to newly emerging pandemic pathogens, such as COVID-19, and equally for intentional releases of advanced or emerging biological threat agents. LLNL’s efforts in identifying treatment options complement the efforts of the National Institutes of Health, the Department of Defense and other Federal agencies by helping to understand the scientific phenomena contributing to disease and, by extension, to apply these capabilities to help the nation with early-stage medical countermeasure discovery.

Several ongoing research projects have been re-directed or started to support rapid identification of medical countermeasures (drugs and vaccines), including:

Vaccine and antibody therapeutic optimization pipeline

Small molecule (drug) discovery modeling

  • The Laboratory is computationally screening over 700 million commercially available small molecule compounds to identify the subset that can be developed into antiviral drugs for COVID-19. When potential candidates are identified, we conduct additional machine learning screens for improving safety and pharmacokinetic profiles of the potential drugs. Initial small molecule predictions are available on the LLNL COVID-19 Data Portal.

Structural protein modeling

  • We are developing computational drug target identification tools to accelerate the process of finding new drugs. Our initial structural predictions for the SARS-CoV2 spike protein are available on the LLNL COVID-19 Data Portal.


For more information about the U.S. government's response to COVID-19, see coronavirus.gov and usa.gov/coronavirus. For the latest public health and safety information from the Centers for Disease Control and Prevention, see cdc.gov/coronavirus.